| 
Research Labs
Sharon Lobert, PhD, RN
The long range goal of her research program is to understand why tumors are resistant to antimitotic chemotherapy agents.
Antimitotic agents have been important in cancer chemotherapy for more than 35 years. Often tumors are resistant to antimitotic agents either initially or after repeated drug cycles. These drugs interact with tubulin, the major protein of mitotic spindles. Mitotic microtubules are dynamic, undergoing assembly and disassembly while aligning chromosomes at the metaphase plate.
Antimitotics halt cell division at metaphase by altering microtubule dynamics. Dr. Lobert has three ongoing projects investigating acute lymphoblastic leukemia, breast cancer and nonsmall cell lung cancer responses to antimitotic drugs, such as paclitaxel and vincristine.
|
|
